Biomedical subjects

Gustav Steinhoff

Publications and source records attributed to Gustav Steinhoff.

4 recordsLinked to original sources

PubMed2003

Autologous bone-marrow stem-cell transplantation for myocardial regeneration.

Implantation of bone-marrow stem cells in the heart might be a new method to restore tissue viability after myocardial infarction. We injected up to 1.5x10(6) autologous AC133+ bone-marrow cells into the infarct border zone in six patients who had had a myocardial infarction and undergone coronary artery bypass grafting. 3-9 months after surgery, all patients were alive and well, global left-ventricular function was enhanced in four patients, and infarct tissue perfusion had improved strikingly in five patients. We believe that implantation of AC133+ stem cells to the heart is safe and might induce angiogenesis, thus improving perfusion of the infarcted myocardium. See Commentary page 11

Aged↗

PubMed2002

Absence of PERV specific humoral immune response in baboons after transplantation of porcine cells or organs.

Xenotransplantation of pig organs seems a promising way of overcoming the prevailing limitation on allotransplantation due to donor numbers. However, as porcine endogenous retroviruses (PERVs) can infect human cells in vitro, there is substantial concern regarding the risk of a PERV infection in xenogeneic transplant recipients. Cultured porcine endothelial cells, stimulated peripheral blood mononuclear cells, and pancreatic islet cells can release PERV infectious for human cells in vitro, but it is currently unknown whether PERV is released in vivo, whether these viral particles can infect the transplant recipient, and whether they are pathogenic. In a retrospective study 15 immunosuppressed baboons were tested for a specific immune response against PERV after transplantation of porcine endothelial cells, mononuclear blood cells, and lungs. Anti-PERV antibody expression was analyzed with peptide-based, enzyme-linked immunosorbent assays and highly sensitive Western Blot assays. This xenotransplantation study using nonhuman primates found no evidence of PERV specific humoral immune response. Our data suggest that no productive PERV infection and no continuous PERV release takes place in the nonhuman primates analyzed in this study.

Animals↗

PubMed2002

[Cardiac tissue engineering].

BACKGROUND: Cardiac tissue engineering is a relatively new interdisciplinary approach to replace diseased cardiovascular tissues with vital structures based on autologous cells. VARIOUS FORMS: This includes the re-seeding of decellularized allogenic or xenogenic scaffolds with autologous cells, the fabrication of organoids based on artificial, biodegradable polymers, and cell transplantation in solid organs. FUTURE CLINICAL APPLICATION: Tissue engineering heart valves, vascular grafts, as well as transplantation of contractile cells or stem cells for myocardial regeneration are not far from their first clinical application. Even though the development of an entirely tissue engineered replacement heart is not yet conceivable, tissue engineering strategies will most likely lead to a significant improvement in the treatment of both acquired and congenital heart disease.

Cell Transplantation↗

PubMed2002

Thoratec left ventricular assist device for bridging to recovery in fulminant acute myocarditis.

Fulminant acute myocarditis can be the cause of rapid cardiac decompensation that is resistant to maximal medical therapy. Successful weaning from left ventricular mechanical support is very rare in fulminant myocarditis. We report the case of a young patient with viral myocarditis who was successfully weaned from a Thoratec left ventricular assist device with full recovery of myocardial function.

Acute Disease↗